Probatebeta
Target

CHRM3

Muscarinic acetylcholine receptor M3

As of the edition of 20 October 2026, CHRM3 (muscarinic acetylcholine receptor M3, UniProt P20309) has 48 drugs tested at it and 57 companies on the list, 5 on route A and 17 on route B.

Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.

The protein

UniProt
P20309
How well studied
Drug target: an approved drug acts on it
Where it sits in the cell
At a membrane
Solved structures
5
Disease areas
Lungs and airways; Urinary and reproductive; Pregnancy and women's health; Immune system; Eye; Nervous system; Mental health; Skin and connective tissue
Registered trials of its drugs
1,148

Drugs at this target

StatusCount
Marketed34
Active1
Went quiet7
Stopped5
Withdrawn from market1
Total48
DrugStatusFurthest phaseUS protection
TiotropiumMarketedPhase 4none listed
GlycopyrroniumMarketedPhase 4none listed
AtropineMarketedPhase 4none listed
SolifenacinMarketedPhase 4none listed
IpratropiumMarketedPhase 4none listed
OxybutyninMarketedPhase 4none listed
TrospiumMarketedPhase 4none listed
FesoterodineMarketedPhase 4none listed
UmeclidiniumMarketedPhase 4Ends 2027
TolterodineMarketedPhase 4none listed
AcetylcholineMarketedPhase 2none listed
AclidiniumMarketedPhase 4none listed

12 of 48 drugs, the most tested first.

Companies at this target

Where the company standsCompanies
Route A5
Route B17
Engaged22
Undetermined13
Total on the list57
Three companies on route A or B, with the route only
CompanyRoute
AbbVieRoute B
NovartisRoute B
AstraZenecaRoute B

The other 54 companies at CHRM3

In the product

57 companies in all; 54 are not named here, and no score is.

See the 57 companies at CHRM3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.

More drugs at CHRM3

Other targets in lungs and airways

Companies holding approvals at CHRM3